A randomized, placebo-controlled, patient and investigator blinded, single dose, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of intra-articular LNA043 in regenerating the articular cartilage of the knee at donor sites in patients undergoing autologous chondrocyte implantation.
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs LNA 043 (Primary)
- Indications Cartilage disorders
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharma A.G.
- 20 Apr 2017 New trial record